A Method of Increasing Red Blood Cell Levels or Treating Anemia in a Patient
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 15 of these applications claim priority to application 61/189,094, filed Aug 14, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,216,997 | Methods for Increasing Red Blood Cell Levels and Treating Anemia Using a Combination of GDF Traps and Erythropoietin Receptor Activators In force · High confidence UsedRemaining | Acceleron Pharma Inc. | In force | High confidence | ||
| US 8,361,957 | An Isolated GDF Trap Polypeptide In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | ||
| US 8,703,927 | Isolated Nucleotide Sequences Encoding GDF Traps In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | ||
| US 9,439,945 | Isolated Nucleotide Sequences Encoding GDF Traps In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | ||
| US 9,505,813 | Use of GDF Traps to Treat Anemia In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | ||
| US 9,932,379 | Isolated Nucleotide Sequences Encoding GDF Traps In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | ||
| US 10,131,700 | Methods for Treating Refractory Anemia with Ringed Sideroblasts In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | ||
| US 10,377,996 | Isolated GDF Trap Polypeptide In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | ||
| US 10,689,427 | Combined Use of GDF Traps and Erythropoietin Receptor Activators to Increase Red Blood Cell Levels In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | ||
| US 10,829,532 | Combined Use of GDF Traps and Erythropoietin Receptor Activators to Increase Red Blood Cell Levels In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | ||
| 10 more records in this group · Pro | ||||||
10 of 20 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 20.
16 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.